$0.57
-0.02 (-4.09%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MBIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLNCT05360238Phase 1: Primary objectiveNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Business reasons | Biological: MB-106 | Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory, Chronic Lymphoid Leukemia in Relapse, B-cell Lymphoma Refractory | 20 | 2024-04-12actual | 2024-07-22 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.NCT05645744observationalAdverse events (AEs) | — | Terminatedsponsor's stated reason: Business Reasons | Biological: Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory | 3 | 2024-04-12actual | 2024-07-22 |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.NCT04109482Phase 1: Safety and Tolerability as measured by the number of patients with treatment related adverse eventsOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Business reasons. | Biological: MB-102 · Drug: Fludarabine, Cyclophosphamide | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 3 | 2023-05-17actual | 2024-07-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19